Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| VTL | Vital Therapies, Inc. | 1.50% | 13.51 | 3.3% | $792.68m | |
| AMGN | Amgen Inc. | -1.30% | 203.33 | 1.3% | $763.42m | |
| GILD | Gilead Sciences, Inc. | -0.87% | 63.55 | 0.9% | $384.95m | |
| CELG | Celgene Corporation | 0.20% | 95.41 | 1.3% | $349.42m | |
| BIIB | Biogen Inc. | -1.93% | 231.17 | 1.3% | $303.35m | |
| ILMN | Illumina, Inc. | -1.01% | 285.74 | 3.5% | $300.78m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -1.49% | 184.30 | 1.9% | $263.05m | |
| EXAS | Exact Sciences Corporation | 1.31% | 119.71 | 24.1% | $251.26m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.63% | 111.97 | 2.0% | $249.39m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.87% | 295.77 | 2.6% | $215.15m | |
| A | Agilent Technologies, Inc. | -0.32% | 71.52 | 1.6% | $205.85m | |
| SRPT | Sarepta Therapeutics, Inc. | -17.39% | 99.39 | 14.7% | $127.10m | |
| INCY | Incyte Corporation | -0.30% | 84.27 | 2.5% | $99.96m | |
| BMRN | BioMarin Pharmaceutical Inc. | -1.67% | 76.12 | 4.3% | $93.13m | |
| GHDX | Genomic Health, Inc. | -0.14% | 74.12 | 1.8% | $90.30m |
Company Profile
Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.